The National Medical Products Administration (NMPA) has released its “Annual Drug Supervision and Administration Statistics (2022)”, offering insights into the drug and device administrative system for the 2022 calendar year.<\/p>\n\n\n\n
Yearly Increase in Clinical Trials and Market Filings<\/strong> Domestic and Overseas Drug Approval Numbers<\/strong>
During the period, the NMPA accepted a total of 2,403 clinical trial filings, marking a 1.6% year-on-year (YOY) increase; 3,714 market filings, up 14.2% YOY; and 5,892 supplementary market filings, up 3.7% YOY. These figures indicate a growing trend in the pharmaceutical and medical device sectors.<\/p>\n\n\n\n
As of the end of 2022, there were 153,713 drug approval numbers produced domestically, up 1.8% YOY. In contrast, there were 2,998 approval numbers for overseas-manufactured drugs, down 35.2% YOY. Among these, 18 innovative drugs were approved for marketing, and 1,615 innovative product candidates were approved for clinical trials, showcasing the NMPA’s focus on fostering innovation in the pharmaceutical industry.<\/p>\n\n\n\n